- Siponimod in the treatment of multiple sclerosis - a case study2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab and siponimod in the treatment of multiple sclerosis - case reports2022 | Faculty of Medicine in Hradec Králové
- Siponimod2020 | First Faculty of Medicine
- Profile of a patient treated with siponimod in routine clinical practice2021 | Faculty of Medicine in Hradec Králové
- Siponimod in the treatment of secondary - progressive multiple sclerosis - case report2022 | Faculty of Medicine in Hradec Králové
- Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Long--term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data2023 | Faculty of Medicine in Hradec Králové
- Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis - current experience2021 | Faculty of Medicine in Hradec Králové
- Long‑term effect of siponimod on MRI outcomes in patients with secondary‑progressive multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Management of secondary-progressive multiple sclerosis2022 | Second Faculty of Medicine
- Profile of a patient with secondary progressive MS - how to identify patients that should be sent to a tertiary Center2021 | Second Faculty of Medicine
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Preventing lymphocyte migration may mean keeping ahead of multiple sclerosis progression2021 | First Faculty of Medicine
- Komentář: Siponimod v léčbě pacientů se sekundárně progresivní roztroušenou sklerózou (studie EXPAND a její analýzy)2020 | First Faculty of Medicine
- The influence on long-term progression of multiple sclerosis - brighter days ahead? The influence on long-term progression of multiple sclerosis - brighter days ahead?2021 | First Faculty of Medicine
- Active secondary progressive multiple sclerosis treatment with a selective sphingosine-1-phosphate receptor modulator2020 | First Faculty of Medicine
- Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals2021 | First Faculty of Medicine